Top

Published in:

01-02-2013 | Viewpoint

A functional link between FOXA1 and breast cancer SNPs

Authors: Madhumohan R Katika, Antoni Hurtado

Published in: Breast Cancer Research | Issue 1/2013

Abstract

Genome-wide association studies have revealed a multitude of breast cancer-associated SNPs. The majority of these SNPs are located in noncoding regions of the genome. Yet how they contribute to breast cancer development is unknown. Recently, a groundbreaking study by the Lupien group has shown that risk-associated SNPs of breast cancer are enriched for FOXA1 binding sites, which influences the function of this transcription factor.

Dowsett M: Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr Relat Cancer. 2001, 8: 191-195. 10.1677/erc.0.0080191.CrossRefPubMed

Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007, 25: 118-145.CrossRefPubMed

Hisamatsu Y, Tokunaga E, Yamashita N, Akiyoshi S, Okada S, Nakashima Y, Aishima S, Morita M, Kakeji Y, Maehara Y: Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer. Ann Surg Oncol. 2012, 19: 1145-1152. 10.1245/s10434-011-2094-4.CrossRefPubMed

Yamaguchi N, Ito E, Azuma S, Honma R, Yanagisawa Y, Nishikawa A, Kawamura M, Imai J, Tatsuta K, Inoue J, Semba K, Watanabe S: FoxA1 as a lineage-specific oncogene in luminal type breast cancer. Biochem Biophys Res Commun. 2008, 365: 711-717. 10.1016/j.bbrc.2007.11.064.CrossRefPubMed

Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS: FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet. 2011, 43: 27-33. 10.1038/ng.730.CrossRefPubMed

Lupien M, Eeckhoute J, Meyer CA, Wang Q, Zhang Y, Li W, Carroll JS, Liu XS, Brown M: FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell. 2008, 132: 958-970. 10.1016/j.cell.2008.01.018.CrossRefPubMedPubMedCentral

Serandour AA, Avner S, Percevault F, Demay F, Bizot M, Lucchetti-Miganeh C, Barloy-Hubler F, Brown M, Lupien M, Metivier R, Salbert G, Eeckhoute J: Epigenetic switch involved in activation of pioneer factor FOXA1-dependent enhancers. Genome Res. 2011, 21: 555-565. 10.1101/gr.111534.110.CrossRefPubMedPubMedCentral

Robinson JL, Macarthur S, Ross-Innes CS, Tilley WD, Neal DE, Mills IG, Carroll JS: Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J. 2011, 30: 3019-3027. 10.1038/emboj.2012.59.CrossRefPubMedPubMedCentral

Frazer KA, Murray SS, Schork NJ, Topol EJ: Human genetic variation and its contribution to complex traits. Nat Rev Genet. 2009, 10: 241-251.CrossRefPubMed

10.

Genomes Project C: A map of human genome variation from populationscale sequencing. Nature. 2010, 467: 1061-1073. 10.1038/nature09534.CrossRef

11.

Cowper-Sal Lari R, Zhang X, Wright JB, Bailey SD, Cole MD, Eeckhoute J, Moore JH, Lupien M: Breast cancer risk-associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expression. Nat Genet. 2012, 44: 1191-1198. 10.1038/ng.2416.CrossRefPubMedPubMedCentral

12.

Bernardo GM, Bebek G, Ginther CL, Sizemore ST, Lozada KL, Miedler JD, Anderson LA, Godwin AK, Abdul-Karim FW, Slamon DJ, Keri R: FOXA1 represses the molecular phenotype of basal breast cancer cells. Oncogene. 2013, 32: 554-563. 10.1038/onc.2012.62.CrossRefPubMed

Title: A functional link between FOXA1 and breast cancer SNPs
Authors: Madhumohan R Katika
Antoni Hurtado
Publication date: 01-02-2013
Publisher: BioMed Central
Published in: Breast Cancer Research / Issue 1/2013
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr3360

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

Mammographic density and risk of breast cancer according to tumor characteristics and mode of detection: a Spanish population-based case-control study

How relevant is hormone receptor status in the context of outcome to HER2-positive breast cancer?

Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening

Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer

Hypoxia stimulates migration of breast cancer cells via the PERK/ATF4/LAMP3-arm of the unfolded protein response

Anti-matrix metalloproteinase-9 DNAzyme decreases tumor growth in the MMTV-PyMT mouse model of breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer